Good morning :)
$
₹
DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc

DMAC

NASDAQ
Asset Logo

DiaMedica Therapeutics Inc

DMAC

NASDAQ
$10.656.55% (+0.65)
$
₹
$10.656.55% (+0.65)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $501.0M the stock is ranked 3296

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

13.01
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.72
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+66.85%

Earnings Growth

-16.07%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 66.85% growth, versus a trailing 3-year CAGR of 54.07%.

2026
Current$9.29Baseline
Analyst Target - 1 year
Target$15.5+66.85%

All values in $

202220232024202520262027$5.33$9.24$13.14Target+66.85%
2026
Current$9.29Baseline
Analyst Target - 1 year
Target$15.5+66.85%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.7Baseline
Forecast for Dec 2026
High$-0.76-8.57%
Average$-0.81-16.07%
Low$-0.88-25.71%

All values in $

202120222023202420252026-0.65-0.52-0.62-0.6-0.7Low-25.71%Average-16.07%High-8.57%
2025
Current$-0.7Baseline
Forecast for Dec 2026
High$-0.76-8.57%
Average$-0.81-16.07%
Low$-0.88-25.71%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-8.6
-0
-8.7
-10
-10.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00013.80000-0.0200
Net Income-5.15-5.11-6.27-7.9-7.70-7.69-8.62-8.74-10.04-10.13
Net Profit Margin----57.23%---31215.40%--
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
DiaMedica Therapeutics Inc -13.01-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare DMAC with any stock or ETF
Compare DMAC with any stock or ETF
Comparing from
DMAC
ABBV
AMGN
Loading...

Frequently asked questions

  1. DiaMedica Therapeutics Inc (DMAC) share price today is $10.65 as of November 5, 2026 at 12:24 AM IST. The stock touched a day high of $10.96 and a day low of $10.35.

  2. DiaMedica Therapeutics Inc stock trades on NASDAQ under the ticker symbol DMAC.

  3. DiaMedica Therapeutics Inc's market capitalization is $500.96M as of November 5, 2026 at 12:24 AM IST.

  4. DiaMedica Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. DiaMedica Therapeutics Inc's price-to-book (P/B) ratio is 13.01 as of November 4, 2026.

  6. Yes, You can buy DiaMedica Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy DiaMedica Therapeutics Inc shares in three steps: 1. Search DiaMedica Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since DiaMedica Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in DiaMedica Therapeutics Inc (DMAC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.9385 shares at the current price of $10.65.

Loading...